MARKET

RNLX

RNLX

Renalytix Plc
NASDAQ
2.990
+0.090
+3.10%
Closed 16:00 02/03 EST
OPEN
2.900
PREV CLOSE
2.900
HIGH
3.100
LOW
2.850
VOLUME
68.15K
TURNOVER
91.84K
52 WEEK HIGH
13.31
52 WEEK LOW
1.050
MARKET CAP
112.79M
P/E (TTM)
-2.3211
1D
5D
1M
3M
1Y
5Y
BRIEF-Renalytix And Partners Awarded $10 Million Grant
Reuters · 01/26 14:43
Renalytix, partners get $10M EU grant to advance treatments for kidney disease
Seeking Alpha · 01/26 13:15
H.C. Wainwright Keeps Their Buy Rating on Renalytix AI (RNLX)
TipRanks · 01/10 11:25
Renalytix Completes Agreement With Veterans Administration To Integrate Kidneyintelx Testing Across All Electronic Health Record Systems
Benzinga · 01/09 12:40
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 12/30/2022 21:32
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/19/2022 21:31
Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript November 30, 2022 Operator: Good morning and welcome to the Renalytix Conference Call to review First Quarter Fiscal 2023 Financial Results. At this time, all participants are in a listen-only mo...
Insider Monkey · 12/07/2022 19:12
HC Wainwright & Co. Maintains Buy on Renalytix, Lowers Price Target to $8
Benzinga · 12/02/2022 18:30
More
About RNLX
Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company. The Company is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Its diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. KidneyIntelX is a bioprognostic methodology. The Company is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations, and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

Webull offers kinds of Renalytix PLC (ADR) stock information, including NASDAQ:RNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RNLX stock methods without spending real money on the virtual paper trading platform.